Lymphatic Filariasis Clinical Trial
Official title:
Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast
NCT number | NCT02032043 |
Other study ID # | 201306100 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | February 2014 |
Est. completion date | December 4, 2017 |
Verified date | May 2018 |
Source | Washington University School of Medicine |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Approximately 4,000 people will participate per year. The study population will include
females and males over 5 years of age who live in filariasis and onchocerciasis endemic
areas. Subject selection will not be based on health status.
Two sites will be studied, and each study will last for 4 years. Participants will be studied
only once in cross-sectional surveys. Some subjects may be included in more than one annual
population survey, but this is not a longitudinal study.
Investigators will compare annual and semiannual mass drug administration (MDA) for lymphatic
filariasis and onchocerciasis, and investigators will compare the impact of these MDA
schedules on soil transmitted helminth infections. MDA will be administered by others
(Ivorian Ministry of Health).
The investigators will test the hypothesis that semiannual mass drug administration (MDA) is
superior to annual MDA for elimination of lymphatic filariasis, onchocerciasis and for
control of soil transmitted helminth (STH) infections.
1. Compare the relative impact and cost effectiveness of annual vs. twice yearly mass drug
administration (MDA) for elimination of lymphatic filariasis (LF) in these populations.
2. Compare the relative impact and cost effectiveness of annual vs. twice yearly mass drug
administration (MDA) for elimination of onchocerciasis in these populations.
3. Study the impact of annual vs. semiannual MDA on soil transmitted helminth (STH)
infection in these populations.
Status | Completed |
Enrollment | 14457 |
Est. completion date | December 4, 2017 |
Est. primary completion date | December 4, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 5 Years and older |
Eligibility |
Inclusion Criteria: - Study areas should be endemic for filariasis and onchocerciasis. - Study population have limited or no prior experience with MDA. Males and Females greater than or equal to 5 years of age. Exclusion Criteria: - Children less than 5 years of age. - Children who weigh less than 15 kg (33 lb) |
Country | Name | City | State |
---|---|---|---|
Côte D'Ivoire | Ivory Coast National Program Against Schistosomiasis, Geohelminths and Filariasis | Abidjan | Lagune-Cocody |
Lead Sponsor | Collaborator |
---|---|
Washington University School of Medicine |
Côte D'Ivoire,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Microfilaria prevalence based on results of microscopic examination of blood smears and skin snips. | From annual population based surveys, the prevalence of microfilaremia (filarial parasites in the blood or skin snips) will be assessed by microscopic examination of slides with thick blood smears and skin snips. Test results for individuals are either positive or negative. The unit for prevalence studies is the percentage (%) of individuals with positive tests. | 4 years | |
Secondary | Prevalence of filarial antigenemia in blood and intensity of filarial and intestinal worm infections based on results of microscopy. | Secondary outcomes for the study include prevalence of filarial antigenemia (detected with the Alere Filariasis Strip test) and prevalence of worm eggs in stool detected by the Kato-Katz test. Both of these outcomes are qualitative with no units of measure (positive or negative). Other secondary outcome measures will be intensity of infection by counting microfilaria (Mf) in blood (Mf per ml of blood) and counting Mf in skin (Mf per milligram) and by counting worm eggs (eggs per gram of stool, assessed separately for each parasite species). All of these quantitative assessments are based on counting parasites by microscopy. | 4 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00300768 -
Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection
|
Phase 2 | |
Not yet recruiting |
NCT04035174 -
Evaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central Africa
|
N/A | |
Recruiting |
NCT03653975 -
Clinical Features and Potential Etiology of Epilepsy and Nodding Syndrome in the Mahenge Area, Ulanga District
|
||
Completed |
NCT03052998 -
Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy
|
Phase 4 | |
Active, not recruiting |
NCT04311671 -
Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole
|
Phase 3 | |
Active, not recruiting |
NCT03876262 -
Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis
|
Phase 3 | |
Terminated |
NCT04913610 -
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection
|
Phase 2 | |
Completed |
NCT03962062 -
A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years
|
Phase 1 | |
Completed |
NCT01905436 -
Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia
|
||
Recruiting |
NCT00001230 -
Host Response to Infection and Treatment in Filarial Diseases
|
||
Completed |
NCT05750043 -
Effect of Onchocerciasis Elimination Measures on the Incidence of Epilepsy in Maridi, South Sudan
|
||
Completed |
NCT05749653 -
Impact of a Bi-annual CDTI on the Incidence of Epilepsy in an Onchocerciasis-endemic Area
|
N/A | |
Completed |
NCT02078024 -
Efficacy of Ivermectin and Albendazole Against Onchocerciasis in the Volta Region, Ghana
|
Phase 3 | |
Completed |
NCT00127504 -
Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness
|
Phase 2 | |
Completed |
NCT03131401 -
Prevalence of LF Infection in Districts Not Included in LF Control Activities
|
||
Completed |
NCT04188301 -
Safety and Efficacy of IDA for Onchocerciasis
|
Phase 2 | |
Terminated |
NCT05084560 -
Development of AWZ1066S, a Small Molecule Anti-Wolbachia Candidate Macrofilaricide Drug
|
Phase 1 | |
Completed |
NCT03517462 -
Ocular Changes After Ivermectin - (DOLF IVM/Oncho)
|
N/A | |
Active, not recruiting |
NCT05180461 -
Emodepside Phase II Trial for Treatment of Onchocerciasis
|
Phase 2 | |
Enrolling by invitation |
NCT06070116 -
Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis
|
Phase 2 |